Cancer Council Victoria | Victorian Cancer Trials Link

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Clinical summary

In this trial patients will be randomised to receive DS-8201a, sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously, OR T-DM1 according to the approved label.

Conditions

This trial is treating patients with HER2-positive breast cancer

Trial Acronym
Destiny-Breast 03

Trial Identifiers
NCT03529110

Cancer
Breast

Age: 18+
Phase: III

For full trial details, visit trials.cancervic.org.au/details/vctl_nct03529110